TCRT
ALAUNOS (TCRT)
NASDAQ
$2.09+$0.0010 (+0.05%)
Price as of Jul 13, 2026 6:46 PM EDT
  • $5.0M
    Market Cap
  • -47.90%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 46
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

No data found

No data found

Peers

Statistics

More
Day Range
$2.03
$2.10
$2.08
1-Year Range
$1.77
$4.36
$2.08
Latest Close$2.08
Change
+$0.03 (+1.63%)
Volume7,548
Market Cap$5.0M
Shares Outstanding2.4M
P/E (TTM)-1.01
Diluted EPS (TTM)-$2.02
Enterprise Value$4.7M

Information as of 07/13/2026

Company Profile

ALAUNOS THERAPEUTICS INC
ALAUNOS THERAPEUTICS INC
https://www.alaunos.com
$5.0M
Market Cap
-$4.1M
Net Income
Sector: Healthcare
Industry: Biotechnology
501 E. Las Olas Blvd., Fort Lauderdale, FL, United States, 33301
346 355 4099

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Key Executives

  • Holger Weis
  • Ferdinand Groenewald

Current Ownership Distribution

  • Institutions572.0M (78.96%)
  • Mutual Funds147.5M (20.36%)
  • Insiders4.9M (0.68%)
  • Other0 (0.00%)